Hypersensitivity Clinical Trial
Official title:
Evaluation of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, by Skin Testing
Verified date | December 2015 |
Source | Biomay AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | Austria: Agency for Health and Food Safety |
Study type | Interventional |
The aim of the present skin test study CS-BM32-001 is to evaluate whether the BM32 proteins exhibit low/no allergenic activity when applied by skin prick- and atopy patch testing to grass pollen allergic patients
Status | Completed |
Enrollment | 60 |
Est. completion date | September 2011 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Positive history of grass pollen allergy and positive skin prick test reaction to grass pollen extract - Age between 18 and 60 years - Subjects must have a standard health care insurance - Subject must appear capable to understand and comply with all relevant aspects of the study protocol Exclusion Criteria: - pregnancy or breast feeding - autoimmune diseases, immune defects including immuno- suppression, immune-complex-induced immunopathies - contra-indication for adrenaline - severe general maladies, malignant diseases - patients under long-term treatment with systemic corticosteroids, immunosuppressive drugs, tranquilizers or psychoactive drugs - contra-indications for skin prick testing such as: skin inflammation in the test area, urticaria facticia, unstable or uncontrolled bronchial asthma (30) - use of beta-blockers - participation in another clinical trial within one month prior to the study; however, participation during the previous month solely in the form of blood donation without other interventions will be acceptable - risk of non-compliance with the study procedure and restrictions - use of oral H1 antihistamines within the previous 3 days, oral Ketotifen within the previous 5 days and topical corticosteroids in the test area within the previous 14 days. - systemic (short-term) corticosteroids within the previous 14 days |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Medical University | Vienna |
Lead Sponsor | Collaborator |
---|---|
Biomay AG | Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | wheal size of immediate type skin reactions to the mix of BM32 proteins wheal size of immediate type skin reactions to the wheal size of immediate type skin reaction to the mix of BM32 proteins | For skin prick testing a drop of the test solution will be placed on the subjects´ skin at a distance of at least 2 cm between individual application points. The skin will be pricked with sterile prick lancets. Reactions will be recorded after 20 minutes by measuring the diameters of the wheal. Wheals of more than 3 mm diameter will be regarded as positive reactions. | 20 minutes | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531540 -
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
|
Phase 3 | |
Completed |
NCT00988065 -
Sugammadex Hypersensitivity Study (Study P06042)
|
Phase 1 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02588326 -
Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays
|
Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Completed |
NCT01494649 -
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
|
N/A | |
Enrolling by invitation |
NCT05039229 -
Measures for Bioaerosol Reduction in the Salmon Industry
|
N/A | |
Enrolling by invitation |
NCT05675241 -
Characterizing the Inflammation Around Dental Implants
|
||
Completed |
NCT04006106 -
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
|
||
Not yet recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
Phase 4 | |
Completed |
NCT04605471 -
A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Terminated |
NCT05247567 -
Quaternary Ammonium and Immunization in Hairdressers
|
N/A | |
Completed |
NCT05119751 -
Vestibular Versus Sublingual Route of AIT Tablets
|
Phase 4 | |
Recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Not yet recruiting |
NCT04485299 -
Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient
|
Phase 2/Phase 3 | |
Completed |
NCT02686827 -
DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.
|
Phase 2 |